BiotechTube

Blinatumomab + olverembatinib

Phase 2Recruiting
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Phase II Clinical Trial

Conditions

Phase II Clinical Trial, Blinatumomab, Olverembatinib, Lymphoblastic Leukemia, Philadelphia Chromosome Positive

Trial Timeline

Aug 27, 2026 → Sep 30, 2033

NCT ID
NCT07178912

About Blinatumomab + olverembatinib

Blinatumomab + olverembatinib is a phase 2 stage product being developed by Amgen for Phase II Clinical Trial. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07178912. Target conditions include Phase II Clinical Trial, Blinatumomab, Olverembatinib.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT07178912Phase 2Recruiting

Competing Products

20 competing products in Phase II Clinical Trial

See all competitors
ProductCompanyStageHype Score
TERN-701Terns PharmaceuticalsPhase 1/2
38
Tamsulosin HCl + Solifenacin Succinate + EC905Astellas PharmaPhase 1
33
solifenacin succinate + mirabegron + mirabegron/solifenacin succinateAstellas PharmaPhase 1
33
Graceptor®Astellas PharmaPre-clinical
23
Lemborexant + PlaceboEisaiApproved
85
BIW-8962Kyowa KirinPhase 1/2
41
AcalabrutinibAstraZenecaPhase 1/2
41
Sacituzumab tirumotecanMerckPhase 2
52
progesterone + ProgesteroneMerckApproved
85
AsciminibNovartisPre-clinical
23
NilotinibNovartisPhase 3
77
Imatinib mesylateNovartisPhase 3
77
Imatinib Mesylate 600 MG Oral Tablet + Imatinib Mesylate 400 MG Oral Tablet + Imatinib MesylateNovartisPhase 3
77
ribociclib + TrametinibNovartisPhase 1
33
NilotinibNovartisApproved
85
ImatinibNovartisPhase 3
77
NilotinibNovartisApproved
85
GleevecNovartisPhase 2
52
Nilotinib + RuxolitinibNovartisPhase 1/2
41
ABL001NovartisPhase 3
77

Other Products from Amgen

Aranesp®Approved
84
PanitumumabApproved
84
EvolocumabApproved
84
Prolia®Approved
84
EvolocumabApproved
84